A provider charging $150 per month with no clinical oversight is a worse deal than one charging $300 with proper monitoring, dosage adjustment, and access to a real clinician
Despite all the changes, it seems likely that compounding pharmacies will continue to offer GLP-1 drugs, at least for the foreseeable future, says Brunner: Some patients will be able to maintain these therapies at a price point they can afford in a customized formulation. The Takeaway The FDA ordered compounding pharmacies to stop producing and selling copies of GLP-1 injectable drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, as official shortages have ended
You are not seeing the full picture
Understanding what drives pricing differences helps you distinguish genuine value from false economy
Most people at 1.5 mg weekly are seeing noticeable changes in hunger patterns and early weight loss results
And some research suggests it supports cardiovascular function by improving the efficiency of cardiac energy metabolism
